At the US Food and Drug Administration (FDA)–approved every-2-weeks dosing schedule, peginterferon β-1a (Plegridy, Biogen Idec) maintains efficacy for up to 6 years in adults with relapsing-remitting multiple sclerosis (RRMS), new long-term data suggest.
Over 6 years, the adjusted ARR was significantly improved with peginterferon β-1a every 2 weeks compared with the -4-weeks regimen (0.188 vs 0.263; rate ratio, 0.714; 95% confidence interval, 0.563 - 0.904; P = .0052). Year-over-year adjusted ARRs were generally reduced in the every-2-weeks group.
http://www.medscape.com/viewarticle/862335
Over 6 years, the adjusted ARR was significantly improved with peginterferon β-1a every 2 weeks compared with the -4-weeks regimen (0.188 vs 0.263; rate ratio, 0.714; 95% confidence interval, 0.563 - 0.904; P = .0052). Year-over-year adjusted ARRs were generally reduced in the every-2-weeks group.
http://www.medscape.com/viewarticle/862335
Comment